We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IDEXX Laboratories, Inc. (IDXX - Free Report) posted first-quarter 2023 earnings per share (EPS) of $2.55, up 12.3% year over year. The figure surpassed the Zacks Consensus Estimate by 7.1%.
Comparable constant-currency EPS totaled $2.60 in the first quarter of 2023, up 17.6% year over year.
Revenues in Detail
First-quarter revenues increased 8% year over year to $900 million. Organically, growth was 10%. The metric exceeded the Zacks Consensus Estimate by 1.5%. The year-over-year upside was primarily driven by 9% reported and 12% organic growth in CAG Diagnostics’ recurring revenues. U.S. CAG Diagnostics’ recurring revenues increased 14% on a reported and organic basis.
Veterinary software, services and diagnostic imaging systems revenues increased 13% as reported and 14% organically, reflecting high growth in recurring revenues and continued strong quarterly placements of cloud-based software solutions.
Segmental Analysis
IDEXX derives revenues from four operating segments — CAG, Water, Livestock, Poultry and Dairy (LPD) and Other.
In the first quarter, CAG revenues rose 9% on a reported basis (up 11% organically) year over year to $827.3 million. The Water segment’s revenues increased 7% (up 8% organically) year over year to $38.8 million. However, LPD revenues dropped 5% on a reported basis (down 2% organically) to $29.2 million. Revenues in the Other segment fell 40.6% on a reported basis to $4.8 million.
Margins
Gross profit in the first quarter rose 8.9% to $542.9 million. Gross margin expanded 70 basis points (bps) to 60.3%.
Sales and marketing expenses rose 11.7% to $147.8 million, while general and administrative expenses dropped 10.1% to $70.1 million. Research and development expenses rose 11.2% to $44.7 million.
IDEXX Laboratories, Inc. Price, Consensus and EPS Surprise
Overall, operating profit in the reported quarter was $280.4 million, up 12.9% year over year. The operating margin in the quarter expanded 146 bps to 31.1%.
Financial Position
IDEXX exited first-quarter 2023 with cash and cash equivalents of $111.4 million compared with $112.5 million recorded at the end of fourth-quarter 2022. Total debt (including the current portion) at the end of the first quarter of 2023 was $771.3 million compared with a total debt of $769.4 million at the end of fourth-quarter 2022.
Cumulative net cash provided by operating activities at the end of the first quarter of 2023 was $183.9 million compared with $114.7 million a year ago.
2023 Guidance
The company updated its full-year 2023 outlook.
For 2023, the company expects revenue growth in the range of $3.615-$3,700, indicating growth of 7.5-10% on a reported and organic basis (up from the previous guidance of $3,590-$3,690 million). The Zacks Consensus Estimate for the same is currently pegged at $3.63 billion.
IDEXX’s full-year EPS guidance is now pegged in the range of $9.33-$9.75, indicating a rise of 16-21% on a reported basis (up from the previous guidance of $9.27-$9.75). The Zacks Consensus Estimate for full-year EPS is currently pegged at $9.61.
Our Take
IDEXX exited the first quarter of 2023 on a decent note, with earnings and revenues beating estimates. The company registered year-over-year growth in revenues on a reported and organic basis. The top line was driven by continued solid demand for veterinary services and benefits from strong IDEXX execution. IDEXX innovation and commercial engagement drove record first-quarter global premium instrument placements. Veterinary software, services and diagnostic imaging systems revenues growth were supported by double-digit organic gains in recurring software and digital imaging revenues. However, LPD revenues declined in the quarter on a reported basis. Further, inflationary pressure has been denting on the bottom line.
Zacks Rank and Key Picks
IDEXX currently carries Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Edwards Lifesciences Corporation (EW - Free Report) , Intuitive Surgical, Inc. (ISRG - Free Report) and Johnson & Johnson (JNJ - Free Report) .
Edwards Lifesciences, carrying a Zacks Rank #2 (Buy), reported first-quarter 2023 adjusted earnings per share (EPS) of 62 cents, beating the Zacks Consensus Estimate by 1.6%. Revenues of $1.46 billion outpaced the consensus mark by 4.7%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Edwards Lifesciences has a long-term estimated growth rate of 6.8%. EW’s earnings surpassed estimates in two of the trailing four quarters, missed the same in one and broke even in the other, the average being 1.2%.
Intuitive Surgical, with a Zacks Rank #2, reported first-quarter 2023 adjusted EPS of $1.23, which beat the Zacks Consensus Estimate by 3.4%. Revenues of $1.70 billion outpaced the consensus mark by 6.9%.
Intuitive Surgical has a long-term estimated growth rate of 13%. ISRG’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average being 1.9%.
Johnson & Johnson reported first-quarter 2023 adjusted earnings of $2.68 per share, beating the Zacks Consensus Estimate by 6.8%. Revenues of $24.75 billion surpassed the Zacks Consensus Estimate by 5%. It currently carries a Zacks Rank #2.
Johnson & Johnson has a long-term estimated growth rate of 5.5%. JNJ’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 3.9%
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
IDEXX (IDXX) Q1 Earnings Beat Estimates, Margins Increase
IDEXX Laboratories, Inc. (IDXX - Free Report) posted first-quarter 2023 earnings per share (EPS) of $2.55, up 12.3% year over year. The figure surpassed the Zacks Consensus Estimate by 7.1%.
Comparable constant-currency EPS totaled $2.60 in the first quarter of 2023, up 17.6% year over year.
Revenues in Detail
First-quarter revenues increased 8% year over year to $900 million. Organically, growth was 10%. The metric exceeded the Zacks Consensus Estimate by 1.5%.
The year-over-year upside was primarily driven by 9% reported and 12% organic growth in CAG Diagnostics’ recurring revenues. U.S. CAG Diagnostics’ recurring revenues increased 14% on a reported and organic basis.
Veterinary software, services and diagnostic imaging systems revenues increased 13% as reported and 14% organically, reflecting high growth in recurring revenues and continued strong quarterly placements of cloud-based software solutions.
Segmental Analysis
IDEXX derives revenues from four operating segments — CAG, Water, Livestock, Poultry and Dairy (LPD) and Other.
In the first quarter, CAG revenues rose 9% on a reported basis (up 11% organically) year over year to $827.3 million. The Water segment’s revenues increased 7% (up 8% organically) year over year to $38.8 million. However, LPD revenues dropped 5% on a reported basis (down 2% organically) to $29.2 million. Revenues in the Other segment fell 40.6% on a reported basis to $4.8 million.
Margins
Gross profit in the first quarter rose 8.9% to $542.9 million. Gross margin expanded 70 basis points (bps) to 60.3%.
Sales and marketing expenses rose 11.7% to $147.8 million, while general and administrative expenses dropped 10.1% to $70.1 million. Research and development expenses rose 11.2% to $44.7 million.
IDEXX Laboratories, Inc. Price, Consensus and EPS Surprise
IDEXX Laboratories, Inc. price-consensus-eps-surprise-chart | IDEXX Laboratories, Inc. Quote
Overall, operating profit in the reported quarter was $280.4 million, up 12.9% year over year. The operating margin in the quarter expanded 146 bps to 31.1%.
Financial Position
IDEXX exited first-quarter 2023 with cash and cash equivalents of $111.4 million compared with $112.5 million recorded at the end of fourth-quarter 2022. Total debt (including the current portion) at the end of the first quarter of 2023 was $771.3 million compared with a total debt of $769.4 million at the end of fourth-quarter 2022.
Cumulative net cash provided by operating activities at the end of the first quarter of 2023 was $183.9 million compared with $114.7 million a year ago.
2023 Guidance
The company updated its full-year 2023 outlook.
For 2023, the company expects revenue growth in the range of $3.615-$3,700, indicating growth of 7.5-10% on a reported and organic basis (up from the previous guidance of $3,590-$3,690 million). The Zacks Consensus Estimate for the same is currently pegged at $3.63 billion.
IDEXX’s full-year EPS guidance is now pegged in the range of $9.33-$9.75, indicating a rise of 16-21% on a reported basis (up from the previous guidance of $9.27-$9.75). The Zacks Consensus Estimate for full-year EPS is currently pegged at $9.61.
Our Take
IDEXX exited the first quarter of 2023 on a decent note, with earnings and revenues beating estimates. The company registered year-over-year growth in revenues on a reported and organic basis. The top line was driven by continued solid demand for veterinary services and benefits from strong IDEXX execution. IDEXX innovation and commercial engagement drove record first-quarter global premium instrument placements. Veterinary software, services and diagnostic imaging systems revenues growth were supported by double-digit organic gains in recurring software and digital imaging revenues. However, LPD revenues declined in the quarter on a reported basis. Further, inflationary pressure has been denting on the bottom line.
Zacks Rank and Key Picks
IDEXX currently carries Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Edwards Lifesciences Corporation (EW - Free Report) , Intuitive Surgical, Inc. (ISRG - Free Report) and Johnson & Johnson (JNJ - Free Report) .
Edwards Lifesciences, carrying a Zacks Rank #2 (Buy), reported first-quarter 2023 adjusted earnings per share (EPS) of 62 cents, beating the Zacks Consensus Estimate by 1.6%. Revenues of $1.46 billion outpaced the consensus mark by 4.7%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Edwards Lifesciences has a long-term estimated growth rate of 6.8%. EW’s earnings surpassed estimates in two of the trailing four quarters, missed the same in one and broke even in the other, the average being 1.2%.
Intuitive Surgical, with a Zacks Rank #2, reported first-quarter 2023 adjusted EPS of $1.23, which beat the Zacks Consensus Estimate by 3.4%. Revenues of $1.70 billion outpaced the consensus mark by 6.9%.
Intuitive Surgical has a long-term estimated growth rate of 13%. ISRG’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average being 1.9%.
Johnson & Johnson reported first-quarter 2023 adjusted earnings of $2.68 per share, beating the Zacks Consensus Estimate by 6.8%. Revenues of $24.75 billion surpassed the Zacks Consensus Estimate by 5%. It currently carries a Zacks Rank #2.
Johnson & Johnson has a long-term estimated growth rate of 5.5%. JNJ’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 3.9%